1231 related articles for article (PubMed ID: 25548469)
21. Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease.
Sipos F; Fűri I; Constantinovits M; Tulassay Z; Műzes G
World J Gastroenterol; 2014 Sep; 20(36):12713-21. PubMed ID: 25278673
[TBL] [Abstract][Full Text] [Related]
22. Myeloid differentiation factor 88-dependent and -independent pathways in toll-like receptor signaling.
Akira S; Hoshino K
J Infect Dis; 2003 Jun; 187 Suppl 2():S356-63. PubMed ID: 12792852
[TBL] [Abstract][Full Text] [Related]
23. Enteroendocrine cells express functional Toll-like receptors.
Bogunovic M; Davé SH; Tilstra JS; Chang DT; Harpaz N; Xiong H; Mayer LF; Plevy SE
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1770-83. PubMed ID: 17395901
[TBL] [Abstract][Full Text] [Related]
24. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.
Yamamoto M; Sato S; Hemmi H; Hoshino K; Kaisho T; Sanjo H; Takeuchi O; Sugiyama M; Okabe M; Takeda K; Akira S
Science; 2003 Aug; 301(5633):640-3. PubMed ID: 12855817
[TBL] [Abstract][Full Text] [Related]
25. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
26. Phosphatase PTP1B negatively regulates MyD88- and TRIF-dependent proinflammatory cytokine and type I interferon production in TLR-triggered macrophages.
Xu H; An H; Hou J; Han C; Wang P; Yu Y; Cao X
Mol Immunol; 2008 Aug; 45(13):3545-52. PubMed ID: 18571728
[TBL] [Abstract][Full Text] [Related]
27. Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer.
Chuffa LG; Fioruci-Fontanelli BA; Mendes LO; Ferreira Seiva FR; Martinez M; Fávaro WJ; Domeniconi RF; Pinheiro PF; Delazari Dos Santos L; Martinez FE
BMC Cancer; 2015 Feb; 15():34. PubMed ID: 25655081
[TBL] [Abstract][Full Text] [Related]
28. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4.
Yamamoto M; Sato S; Hemmi H; Sanjo H; Uematsu S; Kaisho T; Hoshino K; Takeuchi O; Kobayashi M; Fujita T; Takeda K; Akira S
Nature; 2002 Nov; 420(6913):324-9. PubMed ID: 12447441
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of homodimerization of Toll-like receptor 4 by curcumin.
Youn HS; Saitoh SI; Miyake K; Hwang DH
Biochem Pharmacol; 2006 Jun; 72(1):62-9. PubMed ID: 16678799
[TBL] [Abstract][Full Text] [Related]
30. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway.
Lang T; Lo C; Skinner N; Locarnini S; Visvanathan K; Mansell A
J Hepatol; 2011 Oct; 55(4):762-9. PubMed ID: 21334391
[TBL] [Abstract][Full Text] [Related]
31. Commensal and Pathogenic Biofilms Alter Toll-Like Receptor Signaling in Reconstructed Human Gingiva.
Shang L; Deng D; Buskermolen JK; Roffel S; Janus MM; Krom BP; Crielaard W; Gibbs S
Front Cell Infect Microbiol; 2019; 9():282. PubMed ID: 31448244
[TBL] [Abstract][Full Text] [Related]
32. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
Arsenault RJ; Kogut MH; He H
Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
[TBL] [Abstract][Full Text] [Related]
33. Retinal photoreceptor expresses toll-like receptors (TLRs) and elicits innate responses following TLR ligand and bacterial challenge.
Singh PK; Kumar A
PLoS One; 2015; 10(3):e0119541. PubMed ID: 25767877
[TBL] [Abstract][Full Text] [Related]
34. Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy.
Yang Y; Feng R; Wang YZ; Sun HW; Zou QM; Li HB
Immunol Lett; 2020 Jul; 223():1-9. PubMed ID: 32311408
[TBL] [Abstract][Full Text] [Related]
35. Primer: Toll-like receptor signaling pathways--what do rheumatologists need to know?
O'Neill LA
Nat Clin Pract Rheumatol; 2008 Jun; 4(6):319-27. PubMed ID: 18446139
[TBL] [Abstract][Full Text] [Related]
36. Toll-like Receptors in the Vascular System: Sensing the Dangers Within.
Goulopoulou S; McCarthy CG; Webb RC
Pharmacol Rev; 2016 Jan; 68(1):142-67. PubMed ID: 26721702
[TBL] [Abstract][Full Text] [Related]
37. SCIMP is a universal Toll-like receptor adaptor in macrophages.
Luo L; Curson JEB; Liu L; Wall AA; Tuladhar N; Lucas RM; Sweet MJ; Stow JL
J Leukoc Biol; 2020 Feb; 107(2):251-262. PubMed ID: 31468585
[TBL] [Abstract][Full Text] [Related]
38. Toll-like receptors in hepatocellular carcinoma: potential novel targets for pharmacological intervention.
Zou H; Wang WK; Liu YL; Braddock M; Zheng MH; Huang DS
Expert Opin Ther Targets; 2016 Sep; 20(9):1127-35. PubMed ID: 26998881
[TBL] [Abstract][Full Text] [Related]
39. Toll-like receptors' pathway disturbances are associated with increased susceptibility to infections in humans.
Frazão JB; Errante PR; Condino-Neto A
Arch Immunol Ther Exp (Warsz); 2013 Dec; 61(6):427-43. PubMed ID: 24057516
[TBL] [Abstract][Full Text] [Related]
40. TLR signaling.
Kawai T; Akira S
Cell Death Differ; 2006 May; 13(5):816-25. PubMed ID: 16410796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
